Therapeutic management of atypical antipsychotic‑related metabolic dysfunctions using GLP‑1 receptor agonists: A systematic review

Metabolic disorders (MDs) like obesity, dyslipidemia, and type 2 diabetes are more frequently observed in patients diagnosed with psychiatric disorders undergoing treatment with antipsychotics, particularly atypical agents, than in the general population. The second generation of antidiabetics (SGAD...

Descripción completa

Detalles Bibliográficos
Autor principal: Vasiliu, Octavian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265718/
https://www.ncbi.nlm.nih.gov/pubmed/37324512
http://dx.doi.org/10.3892/etm.2023.12054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265718/
https://www.ncbi.nlm.nih.gov/pubmed/37324512
http://dx.doi.org/10.3892/etm.2023.12054

Ejemplares similares